Fundraising Fox

Mulberry Biotherapeutics

Wellesley, US · Founded 2020 · Delaware corporation

Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.

BiotechHealthtech

Founders & leadership

Mulberry Biotherapeutics was founded in 2020 by Gary Brenner and John Mekalanos.

GB
Gary BrennerFounder
JM
John MekalanosFounder
NK
Neil KirbyinChief Executive Officer
SLSusan Luo
Susan LuoinExecutive

Board

PR
Philip R. ReillyBoard director

Reported raises · per SEC filings

Form D private placements

$2.1M disclosed across 1 round · 2021

▶$2.1MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil KirbyExecutive Officer
  • Susan LuoExecutive Officer
  • Philip R. ReillyDirector
Offering amount
$2.8M
Amount sold
$2.1M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Mission BioCapital Platinum Program Holdings LLC4 shared keywordsMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
Modulate Bio3 shared keywordsModulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
Orum Therapeutics Venture Capital3 shared keywordsOrum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.
Transcode Therapeutics3 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Muna Therapeutics3 shared keywordsMuna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.

Companies competing with Mulberry Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Mulberry Biotherapeutics, Inc. Funding Round | Seedtableseedtable.com · Apr 2021

Frequently asked questions

What does Mulberry Biotherapeutics do?
Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.
Who founded Mulberry Biotherapeutics?
Mulberry Biotherapeutics was founded by Gary Brenner, John Mekalanos in 2020.
How much funding has Mulberry Biotherapeutics raised?
Mulberry Biotherapeutics has disclosed $2.1M raised across 1 round.
Where is Mulberry Biotherapeutics headquartered?
Mulberry Biotherapeutics is headquartered in Wellesley, US.